Maravai LifeSciences Holdings, Inc. (MRVI) 10-Year Financial Performance & Capital Metrics

MRVI • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

AboutMaravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases in the United States and internationally. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as plasmid DNA and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. Maravai LifeSciences Holdings, Inc. was incorporated in 2020 and is headquartered in San Diego, California.Show more

Revenue $259M -10.3%
EBITDA -$179M -1143.3%
Net Income -$145M -21.7%
EPS (Diluted) -1.05 -16.7%
Gross Margin 41.79% -13.9%
EBITDA Margin -68.97% -1263.1%
Operating Margin -90.91% -730.0%
Net Margin -55.89% -35.7%
ROE -21.19% -50.9%
ROIC -24.25% -760.4%
Debt/Equity 0.65 -15.6%
Interest Coverage -4.94 -616.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 87 (top 13%)
✓Strong 5Y sales CAGR of 12.6%
✓Trading at only 0.9x book value

✗Weaknesses

✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y12.61%

3Y-31.3%

TTM-30.56%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM46.04%

EPS CAGR

10Y-

5Y-

3Y-

TTM89.07%

ROCE

10Y Avg9.48%

5Y Avg11.71%

3Y Avg2.31%

Latest-20.04%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	123.83M	143.14M	284.1M	799.24M	883M	288.94M	259.19M
Revenue Growth %	-	0.16%	0.98%	1.81%	0.1%	-0.67%	-0.1%
Cost of Goods Sold+	60.77M	66.85M	79.65M	140.56M	168.96M	148.74M	150.88M
COGS % of Revenue	0.49%	0.47%	0.28%	0.18%	0.19%	0.51%	0.58%
Gross Profit+	63.07M	76.29M	204.45M	658.68M	714.04M	140.2M	108.31M
Gross Margin %	0.51%	0.53%	0.72%	0.82%	0.81%	0.49%	0.42%
Gross Profit Growth %	-	0.21%	1.68%	2.22%	0.08%	-0.8%	-0.23%
Operating Expenses+	45.69M	52.3M	84.55M	104.03M	139.83M	171.85M	343.93M
OpEx % of Revenue	0.37%	0.37%	0.3%	0.13%	0.16%	0.59%	1.33%
Selling, General & Admin	41.19M	48.35M	94.25M	100.06M	129.26M	151.39M	161.77M
SG&A % of Revenue	0.33%	0.34%	0.33%	0.13%	0.15%	0.52%	0.62%
Research & Development	4.5M	3.63M	9.3M	15.22M	18.37M	17.28M	19.22M
R&D % of Revenue	0.04%	0.03%	0.03%	0.02%	0.02%	0.06%	0.07%
Other Operating Expenses	87K	322K	-19M	-11.25M	-7.8M	3.18M	162.93M
Operating Income+	16.44M	23.99M	119.9M	554.64M	574.22M	-31.65M	-235.62M
Operating Margin %	0.13%	0.17%	0.42%	0.69%	0.65%	-0.11%	-0.91%
Operating Income Growth %	-	0.46%	4%	3.63%	0.04%	-1.06%	-6.44%
EBITDA+	38.78M	48.07M	145.74M	579.4M	612.32M	17.13M	-178.75M
EBITDA Margin %	0.31%	0.34%	0.51%	0.72%	0.69%	0.06%	-0.69%
EBITDA Growth %	-	0.24%	2.03%	2.98%	0.06%	-0.97%	-11.43%
D&A (Non-Cash Add-back)	22.35M	24.08M	25.84M	24.75M	38.1M	48.78M	56.87M
EBIT	10.9M	24.11M	112.44M	561.02M	571.89M	663.63M	-213.78M
Net Interest Income+	-27.4M	-29.96M	-30.74M	-30.26M	-18.08M	-18.16M	-20.3M
Interest Income	0	0	0	0	2.34M	27.73M	27.4M
Interest Expense	27.4M	29.96M	30.74M	30.26M	20.41M	45.89M	47.7M
Other Income/Expense	-32.93M	-29.84M	-38.21M	-23.88M	-22.74M	649.38M	-25.86M
Pretax Income+	-16.5M	-5.85M	81.7M	530.76M	551.47M	617.74M	-261.48M
Pretax Margin %	-0.13%	-0.04%	0.29%	0.66%	0.62%	2.14%	-1.01%
Income Tax+	417K	-652K	2.88M	61.52M	60.81M	756.11M	-1.86M
Effective Tax Rate %	1.07%	1.45%	0.94%	0.34%	0.4%	-0.19%	0.55%
Net Income+	-17.73M	-8.49M	76.89M	182.04M	220.21M	-119.03M	-144.85M
Net Margin %	-0.14%	-0.06%	0.27%	0.23%	0.25%	-0.41%	-0.56%
Net Income Growth %	-	0.52%	10.06%	1.37%	0.21%	-1.54%	-0.22%
Net Income (Continuing)	-16.91M	-5.2M	78.82M	469.25M	490.66M	-138.38M	-259.62M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	3.61M	3.23M	66.23M	229.86M	360.02M	373.13M	251.92M
EPS (Diluted)+	-0.20	-0.05	2.36	1.56	1.67	-0.90	-1.05
EPS Growth %	-	0.73%	44.87%	-0.34%	0.07%	-1.54%	-0.17%
EPS (Basic)	-0.20	-0.05	7.43	1.59	1.67	-0.90	-1.05
Diluted Shares Outstanding	88.97M	96.65M	96.65M	121.97M	131.69M	131.92M	137.91M
Basic Shares Outstanding	88.97M	96.65M	96.65M	114.79M	131.54M	131.92M	137.91M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	53.8M	60.55M	331.6M	740.04M	847.9M	699.91M	429.15M
Cash & Short-Term Investments	21.87M	24.7M	236.18M	551.27M	632.14M	574.96M	322.4M
Cash Only	21.87M	24.7M	236.18M	551.27M	632.14M	574.96M	322.4M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	15.99M	18.03M	51.02M	117.51M	146.81M	55.72M	38.52M
Days Sales Outstanding	47.13	45.98	65.55	53.67	60.69	70.39	54.25
Inventory	14.31M	14.2M	33.3M	51.56M	43.15M	51.4M	50.08M
Days Inventory Outstanding	85.94	77.54	152.61	133.88	93.22	126.12	121.16
Other Current Assets	0	800K	0	0	25.8M	17.83M	18.14M
Total Non-Current Assets+	485.87M	517.24M	939.09M	1.18B	1.43B	787.54M	579.1M
Property, Plant & Equipment	42.58M	94.31M	101.31M	95.43M	116.59M	222.65M	217.03M
Fixed Asset Turnover	2.91x	1.52x	2.80x	8.38x	7.57x	1.30x	1.19x
Goodwill	224.28M	224.28M	224.28M	152.77M	283.67M	326.03M	159.88M
Intangible Assets	218.13M	197.85M	177.66M	117.57M	216.66M	220.99M	194.96M
Long-Term Investments	0	0	0	0	11.36M	8.56M	0
Other Non-Current Assets	894K	805K	4.16M	4.36M	40.33M	9.32M	7.24M
Total Assets+	539.68M	577.8M	1.27B	1.92B	2.28B	1.49B	1.01B
Asset Turnover	0.23x	0.25x	0.22x	0.42x	0.39x	0.19x	0.26x
Asset Growth %	-	0.07%	1.2%	0.51%	0.19%	-0.35%	-0.32%
Total Current Liabilities+	35.92M	29.56M	130.78M	93.78M	110.14M	87.47M	56.97M
Accounts Payable	3.6M	7.48M	2.98M	8.15M	5.99M	10.73M	11.96M
Days Payables Outstanding	21.65	40.83	13.68	21.17	12.94	26.33	28.93
Short-Term Debt	2.5M	2.5M	6M	6M	5.44M	5.44M	5.44M
Deferred Revenue (Current)	1000K	841K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	22.17M	11.08M	4.17M	18.89M	69.48M	47.62M	0
Current Ratio	1.50x	2.05x	2.54x	7.89x	7.70x	8.00x	7.53x
Quick Ratio	1.10x	1.57x	2.28x	7.34x	7.31x	7.41x	6.65x
Cash Conversion Cycle	111.43	82.69	204.47	166.37	140.97	170.19	146.48
Total Non-Current Liabilities+	355.74M	403.61M	985.17M	1.28B	1.27B	610.1M	374.06M
Long-Term Debt	335.55M	334.78M	528.61M	524.59M	522M	518.71M	290.49M
Capital Lease Obligations	1.84M	52.92M	56.17M	40.91M	51.56M	79.41M	72.49M
Deferred Tax Liabilities	15.86M	14.7M	8.61M	0	0	0	0
Other Non-Current Liabilities	2.5M	1.21M	391.78M	713.64M	693.38M	11.98M	11.09M
Total Liabilities	391.66M	433.17M	1.12B	1.37B	1.38B	697.57M	431.04M
Total Debt+	339.89M	390.2M	590.78M	575.22M	585.26M	610.97M	376.69M
Net Debt	318.02M	365.5M	354.6M	23.95M	-46.88M	36.01M	54.29M
Debt / Equity	2.30x	2.70x	3.82x	1.05x	0.65x	0.77x	0.65x
Debt / EBITDA	8.76x	8.12x	4.05x	0.99x	0.96x	35.66x	-
Net Debt / EBITDA	8.20x	7.60x	2.43x	0.04x	-0.08x	2.10x	-
Interest Coverage	0.60x	0.80x	3.90x	18.33x	28.13x	-0.69x	-4.94x
Total Equity+	148.02M	144.63M	154.75M	545.36M	905.24M	789.88M	577.21M
Equity Growth %	-	-0.02%	0.07%	2.52%	0.66%	-0.13%	-0.27%
Book Value per Share	1.66	1.50	1.60	4.47	6.87	5.99	4.19
Total Shareholders' Equity	144.41M	141.4M	88.51M	315.5M	545.22M	416.75M	325.29M
Common Stock	182.81M	183.91M	2.58M	2.55M	2.55M	2.51M	2.53M
Retained Earnings	-38.24M	-42.38M	854K	184.56M	404.77M	285.74M	140.89M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-167K	-133K	-44K	0	0	0	0
Minority Interest	3.61M	3.23M	66.23M	229.86M	360.02M	373.13M	251.92M

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-186K	24.11M	152.19M	368.57M	535.98M	126.22M	7.46M
Operating CF Margin %	-0%	0.17%	0.54%	0.46%	0.61%	0.44%	0.03%
Operating CF Growth %	-	130.65%	5.31%	1.42%	0.45%	-0.76%	-0.94%
Net Income	-16.91M	-5.2M	78.82M	469.25M	490.66M	-119.03M	-259.62M
Depreciation & Amortization	22.35M	24.08M	25.84M	24.75M	38.1M	48.78M	56.87M
Stock-Based Compensation	2.12M	1.68M	24.63M	10.46M	18.67M	34.59M	49.41M
Deferred Taxes	317K	-1.16M	-5.46M	46.9M	42.32M	754.94M	2.32M
Other Non-Cash Items	7.79M	2.42M	-7.52M	-6.16M	-8.7M	-690.9M	171.1M
Working Capital Changes	-15.84M	2.29M	35.89M	-176.63M	-45.08M	97.84M	-12.61M
Change in Receivables	-4.15M	-1.89M	-33.14M	-70.39M	-22.27M	84.39M	14.36M
Change in Inventory	2.31M	106K	-19.1M	-21.57M	9.46M	649K	377K
Change in Payables	-871K	2.47M	1.18M	676K	-1.58M	5.28M	723K
Cash from Investing+	-3.45M	-17.15M	6.07M	105.66M	-267.61M	-122.31M	-24.32M
Capital Expenditures	-3.61M	-17.15M	-25.41M	-14.85M	-17.09M	-65.55M	-29.66M
CapEx % of Revenue	0.03%	0.12%	0.09%	0.02%	0.02%	0.23%	0.11%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	160K	0	34.5M	548K	-12.17M	12.87M	5.34M
Cash from Financing+	-9.17M	-4.17M	53.21M	-159.05M	-187.5M	-61.09M	-235.71M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	-52.06M	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	-12.53M	-1.3M	-100.91M	-154.76M	-184.42M	-55.3M	443K
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-3.8M	6.97M	126.78M	353.72M	518.89M	60.67M	-22.19M
FCF Margin %	-0.03%	0.05%	0.45%	0.44%	0.59%	0.21%	-0.09%
FCF Growth %	-	2.83%	17.2%	1.79%	0.47%	-0.88%	-1.37%
FCF per Share	-0.04	0.07	1.31	2.90	3.94	0.46	-0.16
FCF Conversion (FCF/Net Income)	0.01x	-2.84x	1.98x	2.02x	2.43x	-1.06x	-0.05x
Interest Paid	25.68M	28.73M	28.92M	27.23M	20.2M	0	50.97M
Taxes Paid	97K	802K	5.01M	22.47M	23.03M	0	670K

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-11.98%	-5.8%	51.37%	52%	30.36%	-14.04%	-21.19%
Return on Invested Capital (ROIC)	2.65%	3.69%	17.64%	77.13%	60.33%	-2.82%	-24.25%
Gross Margin	50.93%	53.3%	71.96%	82.41%	80.87%	48.52%	41.79%
Net Margin	-14.32%	-5.93%	27.06%	22.78%	24.94%	-41.19%	-55.89%
Debt / Equity	2.30x	2.70x	3.82x	1.05x	0.65x	0.77x	0.65x
Interest Coverage	0.60x	0.80x	3.90x	18.33x	28.13x	-0.69x	-4.94x
FCF Conversion	0.01x	-2.84x	1.98x	2.02x	2.43x	-1.06x	-0.05x
Revenue Growth	-	15.59%	98.48%	181.33%	10.48%	-67.28%	-10.3%

Revenue by Segment

	2021	2022	2023	2024
Nucleic Acid Production	-	-	224.77M	196.34M
Nucleic Acid Production Growth	-	-	-	-12.65%
Biologics Safety Testing	-	-	64.18M	62.84M
Biologics Safety Testing Growth	-	-	-	-2.09%
Shipping and Handling	3.6M	3.2M	-	-
Shipping and Handling Growth	-	-11.11%	-	-

Revenue by Geography

	2021	2022	2023	2024
North America	-	-	141.06M	127.09M
North America Growth	-	-	-	-9.90%
Asia Pacific	-	-	97.44M	89.38M
Asia Pacific Growth	-	-	-	-8.27%
EMEA	-	-	49.92M	42.05M
EMEA Growth	-	-	-	-15.76%
Latin And Central America	-	-	527K	662K
Latin And Central America Growth	-	-	-	25.62%

Frequently Asked Questions

Growth & Financials

Maravai LifeSciences Holdings, Inc. (MRVI) reported $192.3M in revenue for fiscal year 2024. This represents a 55% increase from $123.8M in 2018.

Maravai LifeSciences Holdings, Inc. (MRVI) saw revenue decline by 10.3% over the past year.

Maravai LifeSciences Holdings, Inc. (MRVI) reported a net loss of $121.2M for fiscal year 2024.

Dividend & Returns

Maravai LifeSciences Holdings, Inc. (MRVI) has a return on equity (ROE) of -21.2%. Negative ROE indicates the company is unprofitable.

Maravai LifeSciences Holdings, Inc. (MRVI) had negative free cash flow of $66.3M in fiscal year 2024, likely due to heavy capital investments.

US Stock Screener

...

Maravai LifeSciences Holdings, Inc. (MRVI) 10-Year Financial Performance & Capital Metrics

MRVI • • Industrial / General

HealthcareBiotechnologyPlatform & Technology CompaniesAntibody Discovery Platforms

Revenue $259M -10.3%
EBITDA -$179M -1143.3%
Net Income -$145M -21.7%
EPS (Diluted) -1.05 -16.7%
Gross Margin 41.79% -13.9%
EBITDA Margin -68.97% -1263.1%
Operating Margin -90.91% -730.0%
Net Margin -55.89% -35.7%
ROE -21.19% -50.9%
ROIC -24.25% -760.4%
Debt/Equity 0.65 -15.6%
Interest Coverage -4.94 -616.3%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 87 (top 13%)
✓Strong 5Y sales CAGR of 12.6%
✓Trading at only 0.9x book value

✗Weaknesses

✗Negative free cash flow
✗Trading more than 30% below 52-week high
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-

5Y12.61%

3Y-31.3%

TTM-30.56%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM46.04%

EPS CAGR

10Y-

5Y-

3Y-

TTM89.07%

ROCE

10Y Avg9.48%

5Y Avg11.71%

3Y Avg2.31%

Latest-20.04%

Peer Comparison

Antibody Discovery Platforms

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
NAGENiagen Bioscience Inc	503.58M	6.31	57.36	19.18%	16.38%	28.91%	2.37%	0.06
BTXBlackRock Technology and Private Equity Term Trust	808.8M	6.93	40.76	-81.13%	87.75%	1.87%	34.27%
HALOHalozyme Therapeutics, Inc.	8.45B	71.82	20.94	22.44%	47.91%	118.17%	5.55%	4.14
RPRXRoyalty Pharma plc	16.97B	39.72	20.80	-3.86%	32.55%	7.95%	16.32%	0.74
REGNRegeneron Pharmaceuticals, Inc.	76.63B	741.92	19.35	8.27%	32.13%	14.79%	4.78%	0.09
GMABGenmab A/S	20.85B	33.85	2.79	30.67%	46.8%	114.25%	36.37%	0.03
DNAGinkgo Bioworks Holdings, Inc.	464.86M	9.58	-0.91	-9.71%	-188%	-60.66%		0.65
PRMEPrime Medicine, Inc.	720.24M	3.99	-2.42		-33.02%	-121.95%		0.27

Profit & Loss

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	123.83M	143.14M	284.1M	799.24M	883M	288.94M	259.19M
Revenue Growth %	-	0.16%	0.98%	1.81%	0.1%	-0.67%	-0.1%
Cost of Goods Sold+	60.77M	66.85M	79.65M	140.56M	168.96M	148.74M	150.88M
COGS % of Revenue	0.49%	0.47%	0.28%	0.18%	0.19%	0.51%	0.58%
Gross Profit+	63.07M	76.29M	204.45M	658.68M	714.04M	140.2M	108.31M
Gross Margin %	0.51%	0.53%	0.72%	0.82%	0.81%	0.49%	0.42%
Gross Profit Growth %	-	0.21%	1.68%	2.22%	0.08%	-0.8%	-0.23%
Operating Expenses+	45.69M	52.3M	84.55M	104.03M	139.83M	171.85M	343.93M
OpEx % of Revenue	0.37%	0.37%	0.3%	0.13%	0.16%	0.59%	1.33%
Selling, General & Admin	41.19M	48.35M	94.25M	100.06M	129.26M	151.39M	161.77M
SG&A % of Revenue	0.33%	0.34%	0.33%	0.13%	0.15%	0.52%	0.62%
Research & Development	4.5M	3.63M	9.3M	15.22M	18.37M	17.28M	19.22M
R&D % of Revenue	0.04%	0.03%	0.03%	0.02%	0.02%	0.06%	0.07%
Other Operating Expenses	87K	322K	-19M	-11.25M	-7.8M	3.18M	162.93M
Operating Income+	16.44M	23.99M	119.9M	554.64M	574.22M	-31.65M	-235.62M
Operating Margin %	0.13%	0.17%	0.42%	0.69%	0.65%	-0.11%	-0.91%
Operating Income Growth %	-	0.46%	4%	3.63%	0.04%	-1.06%	-6.44%
EBITDA+	38.78M	48.07M	145.74M	579.4M	612.32M	17.13M	-178.75M
EBITDA Margin %	0.31%	0.34%	0.51%	0.72%	0.69%	0.06%	-0.69%
EBITDA Growth %	-	0.24%	2.03%	2.98%	0.06%	-0.97%	-11.43%
D&A (Non-Cash Add-back)	22.35M	24.08M	25.84M	24.75M	38.1M	48.78M	56.87M
EBIT	10.9M	24.11M	112.44M	561.02M	571.89M	663.63M	-213.78M
Net Interest Income+	-27.4M	-29.96M	-30.74M	-30.26M	-18.08M	-18.16M	-20.3M
Interest Income	0	0	0	0	2.34M	27.73M	27.4M
Interest Expense	27.4M	29.96M	30.74M	30.26M	20.41M	45.89M	47.7M
Other Income/Expense	-32.93M	-29.84M	-38.21M	-23.88M	-22.74M	649.38M	-25.86M
Pretax Income+	-16.5M	-5.85M	81.7M	530.76M	551.47M	617.74M	-261.48M
Pretax Margin %	-0.13%	-0.04%	0.29%	0.66%	0.62%	2.14%	-1.01%
Income Tax+	417K	-652K	2.88M	61.52M	60.81M	756.11M	-1.86M
Effective Tax Rate %	1.07%	1.45%	0.94%	0.34%	0.4%	-0.19%	0.55%
Net Income+	-17.73M	-8.49M	76.89M	182.04M	220.21M	-119.03M	-144.85M
Net Margin %	-0.14%	-0.06%	0.27%	0.23%	0.25%	-0.41%	-0.56%
Net Income Growth %	-	0.52%	10.06%	1.37%	0.21%	-1.54%	-0.22%
Net Income (Continuing)	-16.91M	-5.2M	78.82M	469.25M	490.66M	-138.38M	-259.62M
Discontinued Operations	0	0	0	0	0	0	0
Minority Interest	3.61M	3.23M	66.23M	229.86M	360.02M	373.13M	251.92M
EPS (Diluted)+	-0.20	-0.05	2.36	1.56	1.67	-0.90	-1.05
EPS Growth %	-	0.73%	44.87%	-0.34%	0.07%	-1.54%	-0.17%
EPS (Basic)	-0.20	-0.05	7.43	1.59	1.67	-0.90	-1.05
Diluted Shares Outstanding	88.97M	96.65M	96.65M	121.97M	131.69M	131.92M	137.91M
Basic Shares Outstanding	88.97M	96.65M	96.65M	114.79M	131.54M	131.92M	137.91M
Dividend Payout Ratio	-	-	-	-	-	-	-

Balance Sheet

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	53.8M	60.55M	331.6M	740.04M	847.9M	699.91M	429.15M
Cash & Short-Term Investments	21.87M	24.7M	236.18M	551.27M	632.14M	574.96M	322.4M
Cash Only	21.87M	24.7M	236.18M	551.27M	632.14M	574.96M	322.4M
Short-Term Investments	0	0	0	0	0	0	0
Accounts Receivable	15.99M	18.03M	51.02M	117.51M	146.81M	55.72M	38.52M
Days Sales Outstanding	47.13	45.98	65.55	53.67	60.69	70.39	54.25
Inventory	14.31M	14.2M	33.3M	51.56M	43.15M	51.4M	50.08M
Days Inventory Outstanding	85.94	77.54	152.61	133.88	93.22	126.12	121.16
Other Current Assets	0	800K	0	0	25.8M	17.83M	18.14M
Total Non-Current Assets+	485.87M	517.24M	939.09M	1.18B	1.43B	787.54M	579.1M
Property, Plant & Equipment	42.58M	94.31M	101.31M	95.43M	116.59M	222.65M	217.03M
Fixed Asset Turnover	2.91x	1.52x	2.80x	8.38x	7.57x	1.30x	1.19x
Goodwill	224.28M	224.28M	224.28M	152.77M	283.67M	326.03M	159.88M
Intangible Assets	218.13M	197.85M	177.66M	117.57M	216.66M	220.99M	194.96M
Long-Term Investments	0	0	0	0	11.36M	8.56M	0
Other Non-Current Assets	894K	805K	4.16M	4.36M	40.33M	9.32M	7.24M
Total Assets+	539.68M	577.8M	1.27B	1.92B	2.28B	1.49B	1.01B
Asset Turnover	0.23x	0.25x	0.22x	0.42x	0.39x	0.19x	0.26x
Asset Growth %	-	0.07%	1.2%	0.51%	0.19%	-0.35%	-0.32%
Total Current Liabilities+	35.92M	29.56M	130.78M	93.78M	110.14M	87.47M	56.97M
Accounts Payable	3.6M	7.48M	2.98M	8.15M	5.99M	10.73M	11.96M
Days Payables Outstanding	21.65	40.83	13.68	21.17	12.94	26.33	28.93
Short-Term Debt	2.5M	2.5M	6M	6M	5.44M	5.44M	5.44M
Deferred Revenue (Current)	1000K	841K	1000K	1000K	1000K	1000K	1000K
Other Current Liabilities	22.17M	11.08M	4.17M	18.89M	69.48M	47.62M	0
Current Ratio	1.50x	2.05x	2.54x	7.89x	7.70x	8.00x	7.53x
Quick Ratio	1.10x	1.57x	2.28x	7.34x	7.31x	7.41x	6.65x
Cash Conversion Cycle	111.43	82.69	204.47	166.37	140.97	170.19	146.48
Total Non-Current Liabilities+	355.74M	403.61M	985.17M	1.28B	1.27B	610.1M	374.06M
Long-Term Debt	335.55M	334.78M	528.61M	524.59M	522M	518.71M	290.49M
Capital Lease Obligations	1.84M	52.92M	56.17M	40.91M	51.56M	79.41M	72.49M
Deferred Tax Liabilities	15.86M	14.7M	8.61M	0	0	0	0
Other Non-Current Liabilities	2.5M	1.21M	391.78M	713.64M	693.38M	11.98M	11.09M
Total Liabilities	391.66M	433.17M	1.12B	1.37B	1.38B	697.57M	431.04M
Total Debt+	339.89M	390.2M	590.78M	575.22M	585.26M	610.97M	376.69M
Net Debt	318.02M	365.5M	354.6M	23.95M	-46.88M	36.01M	54.29M
Debt / Equity	2.30x	2.70x	3.82x	1.05x	0.65x	0.77x	0.65x
Debt / EBITDA	8.76x	8.12x	4.05x	0.99x	0.96x	35.66x	-
Net Debt / EBITDA	8.20x	7.60x	2.43x	0.04x	-0.08x	2.10x	-
Interest Coverage	0.60x	0.80x	3.90x	18.33x	28.13x	-0.69x	-4.94x
Total Equity+	148.02M	144.63M	154.75M	545.36M	905.24M	789.88M	577.21M
Equity Growth %	-	-0.02%	0.07%	2.52%	0.66%	-0.13%	-0.27%
Book Value per Share	1.66	1.50	1.60	4.47	6.87	5.99	4.19
Total Shareholders' Equity	144.41M	141.4M	88.51M	315.5M	545.22M	416.75M	325.29M
Common Stock	182.81M	183.91M	2.58M	2.55M	2.55M	2.51M	2.53M
Retained Earnings	-38.24M	-42.38M	854K	184.56M	404.77M	285.74M	140.89M
Treasury Stock	0	0	0	0	0	0	0
Accumulated OCI	-167K	-133K	-44K	0	0	0	0
Minority Interest	3.61M	3.23M	66.23M	229.86M	360.02M	373.13M	251.92M

Cash Flow

	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-186K	24.11M	152.19M	368.57M	535.98M	126.22M	7.46M
Operating CF Margin %	-0%	0.17%	0.54%	0.46%	0.61%	0.44%	0.03%
Operating CF Growth %	-	130.65%	5.31%	1.42%	0.45%	-0.76%	-0.94%
Net Income	-16.91M	-5.2M	78.82M	469.25M	490.66M	-119.03M	-259.62M
Depreciation & Amortization	22.35M	24.08M	25.84M	24.75M	38.1M	48.78M	56.87M
Stock-Based Compensation	2.12M	1.68M	24.63M	10.46M	18.67M	34.59M	49.41M
Deferred Taxes	317K	-1.16M	-5.46M	46.9M	42.32M	754.94M	2.32M
Other Non-Cash Items	7.79M	2.42M	-7.52M	-6.16M	-8.7M	-690.9M	171.1M
Working Capital Changes	-15.84M	2.29M	35.89M	-176.63M	-45.08M	97.84M	-12.61M
Change in Receivables	-4.15M	-1.89M	-33.14M	-70.39M	-22.27M	84.39M	14.36M
Change in Inventory	2.31M	106K	-19.1M	-21.57M	9.46M	649K	377K
Change in Payables	-871K	2.47M	1.18M	676K	-1.58M	5.28M	723K
Cash from Investing+	-3.45M	-17.15M	6.07M	105.66M	-267.61M	-122.31M	-24.32M
Capital Expenditures	-3.61M	-17.15M	-25.41M	-14.85M	-17.09M	-65.55M	-29.66M
CapEx % of Revenue	0.03%	0.12%	0.09%	0.02%	0.02%	0.23%	0.11%
Acquisitions	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-
Other Investing	160K	0	34.5M	548K	-12.17M	12.87M	5.34M
Cash from Financing+	-9.17M	-4.17M	53.21M	-159.05M	-187.5M	-61.09M	-235.71M
Debt Issued (Net)	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-
Dividends Paid	-52.06M	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-
Other Financing	-12.53M	-1.3M	-100.91M	-154.76M	-184.42M	-55.3M	443K
Net Change in Cash	-	-	-	-	-	-	-
Free Cash Flow+	-3.8M	6.97M	126.78M	353.72M	518.89M	60.67M	-22.19M
FCF Margin %	-0.03%	0.05%	0.45%	0.44%	0.59%	0.21%	-0.09%
FCF Growth %	-	2.83%	17.2%	1.79%	0.47%	-0.88%	-1.37%
FCF per Share	-0.04	0.07	1.31	2.90	3.94	0.46	-0.16
FCF Conversion (FCF/Net Income)	0.01x	-2.84x	1.98x	2.02x	2.43x	-1.06x	-0.05x
Interest Paid	25.68M	28.73M	28.92M	27.23M	20.2M	0	50.97M
Taxes Paid	97K	802K	5.01M	22.47M	23.03M	0	670K

Key Ratios

Metric	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-11.98%	-5.8%	51.37%	52%	30.36%	-14.04%	-21.19%
Return on Invested Capital (ROIC)	2.65%	3.69%	17.64%	77.13%	60.33%	-2.82%	-24.25%
Gross Margin	50.93%	53.3%	71.96%	82.41%	80.87%	48.52%	41.79%
Net Margin	-14.32%	-5.93%	27.06%	22.78%	24.94%	-41.19%	-55.89%
Debt / Equity	2.30x	2.70x	3.82x	1.05x	0.65x	0.77x	0.65x
Interest Coverage	0.60x	0.80x	3.90x	18.33x	28.13x	-0.69x	-4.94x
FCF Conversion	0.01x	-2.84x	1.98x	2.02x	2.43x	-1.06x	-0.05x
Revenue Growth	-	15.59%	98.48%	181.33%	10.48%	-67.28%	-10.3%

Revenue by Segment

	2021	2022	2023	2024
Nucleic Acid Production	-	-	224.77M	196.34M
Nucleic Acid Production Growth	-	-	-	-12.65%
Biologics Safety Testing	-	-	64.18M	62.84M
Biologics Safety Testing Growth	-	-	-	-2.09%
Shipping and Handling	3.6M	3.2M	-	-
Shipping and Handling Growth	-	-11.11%	-	-

Revenue by Geography

	2021	2022	2023	2024
North America	-	-	141.06M	127.09M
North America Growth	-	-	-	-9.90%
Asia Pacific	-	-	97.44M	89.38M
Asia Pacific Growth	-	-	-	-8.27%
EMEA	-	-	49.92M	42.05M
EMEA Growth	-	-	-	-15.76%
Latin And Central America	-	-	527K	662K
Latin And Central America Growth	-	-	-	25.62%

Frequently Asked Questions

Growth & Financials

Maravai LifeSciences Holdings, Inc. (MRVI) reported $192.3M in revenue for fiscal year 2024. This represents a 55% increase from $123.8M in 2018.

Maravai LifeSciences Holdings, Inc. (MRVI) saw revenue decline by 10.3% over the past year.

Maravai LifeSciences Holdings, Inc. (MRVI) reported a net loss of $121.2M for fiscal year 2024.

Dividend & Returns

Maravai LifeSciences Holdings, Inc. (MRVI) has a return on equity (ROE) of -21.2%. Negative ROE indicates the company is unprofitable.

Maravai LifeSciences Holdings, Inc. (MRVI) had negative free cash flow of $66.3M in fiscal year 2024, likely due to heavy capital investments.